Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an injectable solution for intravenous use. It is used to treat conditions associated with excess gastric acid, such as erosive oesophagitis, stress‑related gastric ulcers, and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor used to manage disorders related to gastric acid hypersecretion.

- Erosive oesophagitis: reduces acid exposure and promotes healing of the esophageal lining. - Stress‑related gastric ulcers: prevents ulcer formation in critically ill patients. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Pantoprazole may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose stools during therapy. - Injection site reactions: redness, swelling, or pain at the IV site.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis that can occur during treatment. - Hypomagnesemia: low magnesium levels that may cause muscle cramps or cardiac rhythm changes. - Stevens‑Johnson syndrome: rare, life‑threatening skin reaction with blistering and mucosal involvement.

When using Nolpaza, clinicians should consider several safety measures.

- Assess renal function: adjust therapy in patients with severe renal impairment. - Monitor magnesium levels: prolonged use may lead to hypomagnesemia. - Evaluate for infection: risk of Clostridioides difficile colitis, especially with concurrent antibiotics. - Use caution in hepatic impairment: dose may need adjustment in severe liver disease. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption of ketoconazole when co‑administered. - Atazanavir: decreased plasma levels of atazanavir. - Clopidogrel: reduced antiplatelet effect of clopidogrel.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Digoxin: potential increase in serum digoxin concentrations. - Methotrexate: reduced clearance, monitor for toxicity.